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Evaluation of NeuroPage as a memory aid for people with 
Multiple Sclerosis: A randomised controlled trial 
 
Memory problems are reported in 40-60% of people with multiple sclerosis 
(MS). These problems affect independence and may limit the ability to benefit 
from rehabilitation. Our aim was to evaluate the effectiveness of NeuroPage for 
people with MS living in the community. A multicentre, single-blind randomised 
controlled crossover trial was conducted. The intervention comprised the 
NeuroPage service, which sends reminder messages to mobile phones at pre-
arranged times. In the control condition participants received “non-memory 
texts”, that is messages not aimed at providing a reminder, for example supplying 
News headlines or sport updates. Outcome measures were completed using postal 
questionnaires after each condition. There were 38 participants, aged 28 to 72 
(mean 48, S.D. 11) and 10 (26%) were men. There were no significant 
differences between NeuroPage and control conditions on the Everyday Memory 
Questionnaire (p=0.41, d=0.02). The number of daily diary items forgotten in the 
NeuroPage condition was significantly less than in the control (9% vs. 31%, 
p=0.01, d=-0.64). Psychological distress was less in the NeuroPage condition 
than control (p=0.001, d=-0.84). Further evaluation of the effect on everyday 
memory is required.  
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Introduction 
Approximately 40-60% of people with multiple sclerosis (MS) have memory problems 
(Rosti-Otajärvi & Hämäläinen, 2014). Many report feeling more restricted by cognitive 
impairments than by limited mobility (Amato, Zipoli, & Portaccio, 2006), and their 
quality of life is decreased (Grima et al., 2000). Cognitive impairment in people with 
MS is often a hidden condition, which brings difficulties in everyday functioning, and 
contributes to depression, anxiety, distress and fatigue (Gilchrist & Creed, 1994; Sá, 
2008). Cognitive impairments may interfere with daily functioning (Engel, Greim, & 
Zettl, 2007), participation in social activities (Thomas, Thomas, Hillier, Galvin & 
Baker, 2006) and employment status (O'Brien, Chiaravalloti, Goverover, & DeLuca, 
2008; Rao et al., 1991). Memory is one of the most commonly affected of cognitive 
functions in people with MS (Benedict et al., 2006) and the most often reported to affect 
daily life (Samartzis, Gavala, Zoukos, Aspiotis & Thomaides, 2014). 
There are two main approaches to memory rehabilitation: restitution and 
compensation (Evans, 2006; Sohlberg & Mateer, 1989). Restitution involves repeated 
practice on tasks that involve the impaired function. Compensatory approaches include 
training in internal memory aids, such as mnemonics; environmental modification; and 
the use of external aids. The most commonly used strategy is the use of external aids to 
reduce the cognitive load and enable successful completion of a task (Linden et al., 
2016). External memory aids do not aim to improve memory, but focus on reducing 
functional problems, by means of recording and accessing information externally 
(Teasell et al., 2007). However, the process of learning to use an external memory aid is 
not straightforward and some people require support to use them (Evans, 2004). 
There are many external memory aids, such as smartphones, voice recorders, 
watches with alarms and paging devices (Dewar, Kopelman, Kapur, & Wilson, 2014). 
They can be used to hold information concerning target behaviours, such as a reminder 
to take medication. Additionally, the content of a reminder may provide monitoring 
information, such as medication needs to be refilled, or output monitoring, such as, 
“have you refilled your medication?”  People with memory problems may have 
difficulty in developing rehabilitation strategies, because they forget to apply 
compensatory techniques that they have been taught. Technological aids may counteract 
this problem, as users do not have to remember to use the device (Lannin et al., 2014; 
Wilson, Evans, Emslie & Malinek, 1997). Johnson, Bamer, Yorkston, and Amtmann 
(2009) surveyed over 1,000 people with MS and found that approximately half of them 
used electronic memory aids.  
Much of the neuropsychological rehabilitation literature on electronic memory 
aids has focussed on NeuroPage, an alpha-numeric paging system that provides 
audio/vibration alerts and is suitable for those with a wide range of memory and other 
cognitive problems (Wilson, Emslie, Quirk, & Evans, 2001; Wilson, Emslie, Quirk, 
Evans, & Watson, 2005; Hersh & Treadgold, 1994). It sends Short Message Service 
(SMS) text messages to mobile phones or pagers, and is widely available. Reminders 
are externally programmed, and therefore NeuroPage requires only limited training or 
learning by the patient to be used effectively (Kapur, Glisky, & Wilson, 2004). 
NeuroPage assists people with memory and planning problems following acquired brain 
injury, in achieving everyday target behaviours, relative to baseline (Fish, Manly, 
Emslie, Evans & Wilson, 2008; Wilson et al., 2005; Wilson et al., 2001).  
Mobile phones and smartphones are ubiquitous in the general population, and 
are portable, socially acceptable and cost-effective (Dewar et al., 2014). Smartphone 
technology has created a Personal Digital Assistant (PDA)-style memory aid within our 
mobile phones, including functions that remind you to perform a specific task when you 
arrive at a certain location. However, people with moderate-severe cognitive 
impairments still need to be trained to use them as an effective memory aid (Svoboda, 
Richards, Leach, & Mertens, 2012).  
The effectiveness of memory rehabilitation programmes for people with MS is 
far from conclusive (Carr, das Nair, Schwartz, & Lincoln, 2014). A Cochrane review 
(das Nair, Martin, & Lincoln, 2016) evaluated the evidence for effectiveness of memory 
rehabilitation for people with MS, and concluded that there was some evidence to 
support the effectiveness of memory rehabilitation for people with MS. Those who had 
memory rehabilitation had better memory functioning compared to those who did not 
receive memory rehabilitation. However, this was based on few studies, many with 
methodological limitations. Furthermore, another systematic review by Goodwin, 
Lincoln, das Nair and Bateman (2017) evaluating the use of external memory aids for 
people with MS, concluded there was insufficient evidence to support or refute the 
effectiveness of external aids for improving memory function in people with MS. 
Therefore there is some suggestion that compensatory strategies, such as memory aids, 
could be effective in reducing everyday memory problems in people with MS but 
further evidence is required.  
There is evidence for the effectiveness of Neuropage (Fish et al., 2008; Wilson, 
Emslie, Quirk & Evans, 1999; Wilson et al., 2005; Wilson et al., 2001, Wilson et al., 
1997), but this is mainly from participants with stroke or traumatic brain injury. 
Although smart phones and mobile phones are used as external memory aids, there has 
been little effort to assess their usefulness (Baddeley, Eysenck & Anderson, 2014). A 
review of NeuroPage, (Martin-Saez, Deakins, Winson, Watson & Wilson, 2011) 
concluded that the service continued to have a role within cognitive rehabilitation. 
Therefore, this study evaluated the effectiveness of NeuroPage for people with MS. 
The aim was to evaluate whether people with MS who used NeuroPage memory 
text messages showed reduced frequency of memory problems in daily life, increased 
attainment of personally identified goals, reduced distress and improved quality of life, 
compared with those who received social text messages, as a control condition. 
 
Methods 
Design 
This was a single-blind, crossover randomised controlled trial (RCT) comparing 
NeuroPage with a control condition comprising social text messages. Treatment 
efficacy was determined by comparing performance on outcome measures completed at 
the end of each condition. No comparison with baseline performance was conducted in 
order to reduce the risk of a false positive result (Bland & Altman, 2011). 
 
Participants 
Participants were recruited from five UK NHS Trusts and through an MS charity event. 
Participants were included if they: 
(1) had been diagnosed with MS more than 12 months before joining the study 
(2) had self-reported memory problems, defined as a score more than 20 on the self-
report version the Everyday Memory Questionnaire (EMQ; Sunderland, Harris 
& Gleave, 1984). This cut-off represents the 25th percentile of a sample of 
people who took part in a memory rehabilitation study (das Nair & Lincoln, 
2012) and therefore comprised those with moderate and severe memory 
problems in daily life 
(3) were aged 18 years or older 
(4) gave informed consent 
 
Participants were excluded if they:  
(1) had cognitive, visual or motor impairment, such that they were unable to use a 
pager or mobile phone 
(2) had another concurrent neurological diagnosis, e.g. epilepsy 
(3) had a concurrent severe medical or psychiatric diagnosis  
(4) were concurrently taking part in other psychological intervention studies  
(5) did not understand English 
Procedure 
At the baseline assessment participants were offered the choice of receiving text 
messages to a pager or mobile phone. Participants and their relatives or carers were 
asked to describe a typical week to elicit problems that they needed help with (e.g., “I 
forget to lock the back door” or “I forget to take my medication”) and to identify target 
behaviours they wanted to achieve (e.g., “I want to remember to take my medication 
every day”). Participants then agreed on reminders that would be helpful to achieve 
these target behaviours. They were shown a list of common reminders to see whether 
they thought any of them would be useful. Participants also identified the type of non-
memory messages they would be happy to receive (e.g., sports news and current 
affairs). 
Self-reported demographic information and details of type of MS and years 
since diagnosis were recorded. A cognitive assessment was conducted to document the 
nature of the memory impairment and to record factors that may be related to treatment 
response. The measures used were: 
 Everyday Memory Questionnaire (EMQ)(Sunderland, Harris, & Baddeley, 
1983) to assess memory functioning in everyday life. The EMQ consists of 28 
items, each describing everyday activities, which may involve memory failure, 
and each item is rated on the frequency of occurrence. Scores range from 0 to 
112, with higher scores suggesting more frequent forgetting.  
 Doors and People Test (Baddeley, Emslie & Nimmo-Smith, 1994) to assess 
memory performance. This battery of four tests yields a single age-scaled 
overall score which is derived from individual measures of visual and verbal 
memory, recall and recognition and forgetting (Evans, Wilson, & Emslie, 1996). 
Scaled scores range from 0 to 19, with lower scores suggesting more impaired 
memory performance, and average performance indicated by a score of 10. 
 Hayling and Brixton tests (Burgess & Shallice, 1997) to assess executive 
functions. The Hayling Test evaluates initiation speed and response suppression, 
and the Brixton Test is a rule detection and rule following task. Sten scores 
range from 1 to 10 with a standard deviation of 2, with lower scores suggesting 
more impaired executive functioning performance, and average performance 
indicated by a score of 5. 
 Test of Everyday Attention (TEA; Robertson, Ward, Ridgeway, & Nimmo-
Smith, 1994) is a battery of eight tasks to measure attentional processes. Age-
scaled scores were derived for each subtest. As with the Doors and People test, 
scores range from 0 to 19, with lower scores suggesting more impaired attention 
performance. 
Participants were randomly allocated to the intervention or the control group on a 1:1 
ratio. Allocation was determined by an independent research assistant, using a 
randomisation sequence prepared in advance of the study, The independent research 
assistant disclosed the group allocation of the participant to the researcher delivering the 
intervention only after the allocation was recorded. Due to the nature of the 
intervention, both the treating researcher and participants were aware of which group 
they had been allocated to. 
Prior to the first condition, the researcher explained the messaging system and 
checked that participants knew how to open new SMS messages on their mobile 
phones. Those who wished to receive the messages to a pager rather than their mobile 
phone were given a demonstration. 
 
Interventions 
 
During the intervention phase, participants received NeuroPage text messages 
for two months sent from a computer based at the Oliver Zangwill Centre for 
Neuropsychological Rehabilitation (OZC) in Ely, UK. NeuroPage messages were based 
on the problems identified at baseline and prompts sent at pre-arranged times. Only 
messages requested or agreed by participants were selected for transmission. 
Participants also chose the wording of the messages and were free to modify these as 
necessary during the trial.  An example is shown in Figure 1. Two days after the start of 
the intervention, participants were contacted by text message to check that the 
NeuroPage messages were being received.  
 
Figure 1 about here 
 
During the control phase, participants received non-memory text messages for 
two months. Participants were free to modify these during the trial. We explained that 
the non-memory messages would be transmitted at the same times and frequency as the 
NeuroPage messages, unless requested otherwise. An example is shown in Figure 2. 
Two days after the start of the control condition, participants were contacted by text 
message to check the control messages were being received. 
 
Figure 2 about here  
 
Any other rehabilitation, e.g. occupational therapy or physiotherapy, continued 
as usual for all participants. Any medication, including MS disease modifying drugs and 
anti-depressants continued as usual for all participants. 
 
Outcomes 
 
Outcomes were assessed at the end of each condition. Questionnaires were posted to 
participants two days prior to the end of the condition, with a pre-paid addressed return 
envelope. Three weeks were allowed for completion between conditions. Participants 
were sent a text reminder two weeks after each condition ended if the completed 
questionnaires had not been received. If participants reported that they were unable to 
complete the questionnaires, they were asked to complete the EMQ over the phone. 
 
The primary outcome measure was the Everyday Memory Questionnaire (EMQ) 
28 self-report version. The EMQ has been employed in previous studies evaluating 
memory rehabilitation for people with MS (Carr et al., 2014; das Nair & Lincoln, 2012; 
Lincoln et al., 2002). 
 
Secondary outcomes were assessed on the following questionnaires. 
 Everyday Memory Questionnaire 28 informant-report version.  
 General Health Questionnaire 30 (GHQ)(Goldberg & Williams, 1988) to assess 
psychological distress. This measures common mental health problems, 
including depression, anxiety, somatic symptoms and social withdrawal. Scores 
range from 0 to 90, with a higher total score on GHQ indicating more reported 
distress. 
 EQ-5D was used to assess health status (The EuroQol Group, 1990). It has five 
dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) which are each rated at three levels: no problem, some 
problems, extreme problems. Scores range from 1 to 3, with a higher score on 
each item indicating a poorer quality of life. A visual analogue scale gives an 
overall rating of quality of life on a scale from 0 to 100.  
 Adaptation to Memory Difficulties Outcome questionnaire (AMEDO)(Chouliara 
& Lincoln, 2015)  was used to assess coping with memory problems. Part A 
comprises questions about how participants cope with their memory problems, 
ranked on a 4-point Likert scale; Part B includes checklists of memory aids 
used, and questions on how participants use them. Scores range from 15 to 60 in 
part A and from 4 to 16 in part B, with a lower score on AMEDO indicating 
poorer coping strategies for memory problems; and poorer use of external and 
internal aids respectively. 
 The daily diary, completed in the final two weeks of each condition, was used as 
a self-defined outcome measure relating to participants’ everyday memory 
problems.  Participants recorded the frequency of forgetting the tasks they 
received reminders for. The daily diary has been used in previous studies 
evaluating NeuroPage (Fish et al., 2008; Wilson et al., 2001; Wilson et al., 
1997).  Scores range from 0 to 100%, with higher scores indicating more 
frequent forgetting. 
Outcome measures were scored and entered into a password protected database 
by a researcher blind to group allocation. 
  
Statistical methods 
Statistical analyses were carried out using IBM SPSS Statistics version 22.0.  
Intention-to-treat analysis was used.  
Paired analysis was used, as recommended for crossover trials (Elbourne et al., 
2002). For all outcome measures, scores from both groups were combined to get a 
dataset for performance after the NeuroPage condition and after the control condition. A 
paired t-test (Higgins & Green, 2013) was used to compare performance after the 
NeuroPage and control conditions. Bonferroni adjustments were not performed based 
on the view that they are “unnecessary” and increase the likelihood of type II errors, so 
that truly important differences are deemed non-significant (Armstrong, 2014; Perneger, 
1998).  
Effect sizes were estimated using Cohen’s d (Cohen, 1988; Field, 2013), and were 
classified as: 0.2 small, 0.5 moderate, 0.8 large. 
Ethical approval was granted by the National Research Ethics Committee - East 
Midlands (Northampton, reference 13/EM/0324). Research and Development approvals 
were also granted by the National Health Service (NHS) Trusts which were our 
recruiting sites.  
Results 
 
Recruitment 
Of the 107 people referred to the trial, 103 were assessed for eligibility and 4 could not 
be contacted. Of the 103 assessed, 55 were excluded: 8 people did not score above the 
cut-off on the EMQ, 4 were unable to use a pager or phone, 41 did not want to take part, 
and 2 could not be contacted. Ten participants did not receive the messages as planned 
at the beginning of the trial and therefore the trial was restarted. Figure 3 shows the flow 
of participants through the trial. 
 
Figure 3 about here 
 
Outcomes analysis was conducted on 38 participants who were randomised after 
problems were rectified. Seventeen participants were randomised into group 1 and 
received NeuroPage then control, and 21 were randomised to group 2 and received 
control then NeuroPage. The demographic characteristics of the participants are shown 
in Table 1.  
 
Table 1 about here 
Baseline data 
 
The distribution of scores on baseline measures is shown in Table 2. 
 
Table 2 about here 
Outcomes 
 
The demographic characteristics and cognitive test performance of the groups 
were comparable at baseline. Scores on the Doors & People subtests were mainly in the 
low to below average memory ability range. Performance on the Hayling & Brixton 
tests showed mainly below average executive functioning. Overall scores on the Test of 
Everyday Attention were mainly below to low-average.  
No participants dropped out from the intervention phase. One participant 
withdrew part way through the control condition.  
A total of 885 reminder messages were requested in the NeuroPage condition 
and 788 in the control condition. The frequency and type of reminders are shown in 
Table 3.  Messages regarding medication were the most commonly requested reminder 
in the NeuroPage condition. Messages requesting current affairs headlines were the 
most frequently requested in the control condition. One participant opted to receive 
messages to a pager and 37 participants chose to receive messages to their mobile 
phones. 
 
Table 3 about here 
 
The comparison of the two conditions is shown in Table 4. 
 
Table 4 about here 
 
There were significant differences between intervention and control conditions 
on the GHQ30, EQ5D anxiety/depression scale and the daily diary.  Participants had 
less psychological distress and a lower frequency of forgetting everyday target 
behaviours while receiving NeuroPage compared to the control condition. There were 
no significant differences between NeuroPage and control conditions in the frequency 
of everyday memory problems, as rated by participants or informants, adaptation to 
memory difficulties or quality of life scales (mobility, self-care, usual activities and 
pain/discomfort). A large effect size was found for the GHQ30, and moderate effect size 
for the daily diary. 
 
Discussion 
Overall the study showed that receiving memory-related text messages had no effect on 
the self-reported overall frequency of memory problems in daily life, however there was 
a suggestion of beneficial effects on distress and the attainment of personal target 
behaviours. The lack of significant difference between conditions on the EMQ, suggests 
that the content of the messages may not affect the overall frequency of everyday 
memory problems.  
However, we found that there was a moderate effect size and significant 
difference between conditions on the daily diary, demonstrating that participants 
showed better attainment of target behaviour when receiving NeuroPage messages, 
compared to the control condition. This discrepancy suggests that NeuroPage helped 
participants compensate for memory problems on the discrete recall of specific tasks, 
rather than in general, and suggests the content of the message was important in helping 
participants remember.  
The EMQ assesses the overall frequency of everyday memory problems, and 
may not detect changes which are confined to prospective memory functioning. In 
future studies, it would be useful to include a measure of prospective memory, such as 
the Prospective and Retrospective Memory Questionnaire (PRMQ; Smith, Della Sala, 
Logie & Maylor, 2000). These findings are consistent with three previous studies 
evaluating memory rehabilitation for people with MS, where no significant effect of 
treatment was detected on the EMQ (Carr et al., 2014; das Nair & Lincoln, 2012; 
Lincoln et al., 2002). However, there was no appropriate alternative measure of 
everyday memory available that has been shown to be responsive to the effects of 
memory rehabilitation. 
A large effect size and significant difference between conditions was found on 
the GHQ, where participants reported fewer symptoms of psychological distress while 
receiving NeuroPage than when receiving control messages. These findings were 
supported by a significant difference on the anxiety and depression question on the 
EQ5D. Another study by Carr et al. (2014) found that attending a group memory 
rehabilitation significantly improved mood in people with MS compared to usual care. 
Therefore, one explanation might be that receiving the reminder messages may have 
reduced participants’ distress because they were remembering to do the things they 
needed to do, and so their everyday life was easier. However, it is also possible that the 
control condition increased distress and therefore further research is necessary to 
establish how the two conditions impacted on the reported levels of distress. 
No differences between conditions were found on AMEDO, a scale that was 
developed as an outcome measure for memory rehabilitation. This may be because the 
AMEDO may be more appropriate for detecting effects of a comprehensive 
rehabilitation programme that aims to educate and train a variety of memory strategies. 
NeuroPage only aimed to support specific prospective memory problems, and so 
participants were unlikely to endorse questions such as “I understand how memory 
works” or “I have a range of internal memory aids that I can use for different tasks”. 
The cross-over design allowed the comparison of the intervention to an active 
control, with randomisation, allocation concealment and blinding, to eliminate bias. 
However, although a washout period of three weeks was used to reduce carryover 
between conditions, some carryover may have occurred. A parallel arm RCT would 
have resolved this problem. However, one benefit of crossover trials is that participants 
experience both conditions, and can therefore express a preference for or against the 
treatments. Another benefit is that because each patient receives both conditions, 
crossover trials usually require half the number of participants to produce the same 
precision as a parallel group trial (Elbourne et al., 2002).  
Due to the “home-based” nature of the intervention, adherence remains 
unknown. A literature review on the non-use of assistive technology devices reported 
high rates of non-adherence (Wessels, Dijcks, Soede, Gelderblom, & De Witte, 2003). 
Therefore, some reminder messages may not have been read, and mobile phones may 
have been switched off or on silent mode. These events may also have occurred in the 
control condition and therefore been counterbalanced. However, future studies using 
more modern technologies may be able to detect when and how frequently information 
was accessed. 
The EMQ and AMEDO were chosen on the basis of being self-report measures 
of cognitive problem in daily life. However subjective measures rely on participants’ 
ability to report recent or current status, which require intact meta-memory skills, and 
these may be impaired in people with MS (Beatty & Monson, 1991). People with worse 
memories may be worse at recalling memory failures and give themselves low 
frequency ratings (Sunderland et al.,1983). However, the self-report results on the EMQ 
were consistent with the informants’ EMQ reports suggesting this is unlikely to have 
affected results (Goodwin, 2016). 
The outcome questionnaires were selected as being well-established for the 
evaluation of memory rehabilitation, and having good psychometric properties. 
Therefore, findings from this study are likely to be included in future meta-analyses. 
However, the EMQ probably is not sensitive to change in the achievement of target 
behaviours, and changes would not be expected on many items with this intervention, 
e.g. recognising faces. Changes important to the individual are often lost on global 
measures, and improvements too small to be statistically significant may still be 
important to the patient (Hanssen, Šaltytė Benth, Beiske, Landrø, & Hessen, 2015; 
Khan, Pallant, & Turner-Stokes, 2008).  
Some participants did not return the outcome questionnaires. It is possible that 
those with the worst memories were under-represented as they forgot to return the 
outcome questionnaires. However, this would be expected in both conditions, and so 
would not affect the comparison. A few participants reported that they did not return 
questionnaires because of low mood. Face to face outcome assessment visits may be 
better in future studies to increase the compliance with follow-up assessments, but this 
may risk assessors becoming unblinded during assessments. 
The decision not to compare outcome to baseline measure performance was 
made to reduce the likelihood of producing false positive results, however including this 
comparison could have helped better understand the nature of behaviour changes over 
the course of the trial. A potential limitation of the analyses was that multiple t-tests 
were performed, and interpreted without using the Bonferroni correction, and hence 
there is an increased likelihood that any significant differences are due to chance.  
Intention-to-treat analysis was used, where all data were categorised as the condition to 
which the participant was allocated. However, it was not possible to check adherence to 
the intervention.  
 The t-tests only included participants’ full data sets which reduced the sample size. No 
imputation of missing values was carried out, and therefore sensitivity analyses were 
not performed. As a result the study may have been underpowered to detect differences 
between conditions. A post hoc sample size calculation (Goodwin, 2016) for a 
definitive trial indicated a sample size 119 would have 80% power to detect a difference 
on the GHQ with an alpha of 5% and allowing for 10% dropout between baseline and 
follow-up. The sample size estimate for the daily diary as an outcome was 37 
participants. These estimates indicate that a full powered trial is achievable. The 
decision to use these measures for the calculations was made in light of the issues found 
with the EMQ in this study, and the recommendations to use a different measure in 
future studies. 
 
Everyday memory improvements were reported on the daily diary, but not on 
the EMQ or AMEDO. These results partially support the recommendations of Cicerone 
and colleagues (2011) and  de Joode, van Heugten, Verhey, and van Boxtel (2010), to 
offer compensatory aids to people with memory problems; and Jamieson, Cullen, 
McGee-Lennon, Brewster and Evans’ (2014) conclusion that there is evidence of 
benefits of prospective memory prompting devices for people with degenerative 
conditions. Therefore, there is some suggestion that people with MS can be supported 
by electronic memory aids to improve the achievement of target behaviours and 
improve mood. 
Previous studies on NeuroPage have compared the intervention to usual-care 
(Wilson et al., 2001; Wilson et al., 2005; Wilson et al., 1997). This study used an active 
control, containing non-reminder content, which has allowed more exploration of the 
active ingredient of the intervention, e.g. the content or the prompting alert. Generally, 
participants had low to below average retrospective memory functioning, as shown by 
baseline assessments, and would not be expected to remember the target behaviour 
without receiving the reminder content. This was found in some participants who lost 
the benefit of NeuroPage when the condition finished. However, many participants 
reported a maintained benefit of NeuroPage into the control condition, which is 
suggestive of intact retrospective memory as they could remember the target behaviour. 
For this subset of participants a prompt was sufficient to trigger recollection of the 
content and perform the target behaviour. These findings mirror those of Fish and 
colleagues (2008) and suggest the most important element of NeuroPage, i.e. content or 
prompt, may be dependent on the nature of user’s individual specific memory 
impairments. 
There was no evidence to suggest that NeuroPage reduced the frequency of 
memory problems in daily life, or improved quality of life. However, there was 
evidence that those who received NeuroPage had better attainment of target behaviours 
and mood compared to control. Comparing NeuroPage with an active control showed 
that the content of the reminder messages appears to be important to the effectiveness of 
NeuroPage. 
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 Table 1. Demographic characteristics of participants. 
 Group 1 Group 2 
Demographic characteristic n Mean SD Range n Mean SD Range 
Age 17 48.8 12.9 28-72 21 46.7 9.7 30-65 
Years since diagnosis 17 10.6 9.8 1-37 21 9.7 9.4 1-33 
Years since last relapse 11 1.4 1.7 0-6 17 2.1 2.3 0-9 
 
Demographic characteristic n %  n %  
Gender Men 6 35 4 19 
Women 11 65 17 81 
Type of multiple 
sclerosis 
Primary progressive 3 18 1 5 
Secondary progressive 5 29 5 24 
Relapsing remitting 8 47 14 66 
Benign 1 6 0 0 
Missing 0 0 1 5 
Education 1-4 GCSEs or NVQ L1 2 12 2 9 
5+ GCSEs or NVQ L2 6 35 6 29 
 2+ A Levels or NVQ L3 1 6 3 14 
Bachelor’s degree or higher degree 5 29 6 29 
Vocational qualifications 3 18 4 19 
Occupation Higher managerial, administrative 
and professional occupations 
2 12 3 14 
Intermediate occupations (Clerical, 
Sales, Service) 
2 12 2 10 
Routine and manual occupations 0 0 1 5 
Never worked and long-term 
unemployed 
0 0 3 14 
Disability retirement/ retirement 13 76 12 57 
Employment Full time 3 18 2 9 
Part Time 1 6 6 29 
Unemployed 13 76 13 62 
Marital Status Never married or civil partnership 2 12 2 10 
Married or civil partnership 13 76 15 71 
No longer married or civil 
partnership 
2 12 4 19 
 Ethnicity White 17 100 21 100 
GCSE General Certificate of Secondary Education 
NVQ National Vocational Qualifications 
A Level Advanced Level 
  
 Table 2. Distribution of scores on baseline measures 
 Group 1  Group 2 
n Mean SD Range n Mean SD Range 
Everyday Memory Questionnaire 17 51.6 17.8 32-86 21 53.3 18.2 21-99 
Doors & People Test Scaled Scores 
People 17 7.8 3.6 1-13 21 7.3 3.5 1-13 
Doors 17 7.3 4.3 1-14 21 6.4 2.9 1-11 
Shapes 17 9.0 5.3 0-16 21 8.8 3.7 0-14 
Names 17 7.4 4.5 0-15 21 10.4 4.1 1-16 
Overall Score 17 7.7 4.6 0-15 21 7.6 4.3 0-13 
Hayling & Brixton Sten scores 
Hayling error 17 5.8 2.0 1-8 21 5.6 1.8 1-8 
Hayling overall  17 5.0 1.7 1-7 21 5.1 1.4 1-6 
Brixton  17 5.2 2.7 1-10 21 5.1 2.3 1-9 
Test of Everyday Attention Age-Scaled scores 
Map search 1  15 7.1 3.4 0-12 21 7.0 3.4 0-12 
Map search 2  15 6.9 3.0 0-11 21 6.5 3.4 0-13 
Elevator counting 17 6.5 0.7 5-7 21 6.9 0.4 6-7 
 Elevator counting with distraction 17 9.2 3.0 5-13 21 10.6 2.3 6-13 
Visual elevator 1 16 8.8 3.6 3-15 20 9.9 2.4 5-14 
Visual elevator 2 16 7.8 4.0 0-13 20 8.3 2.8 2-15 
Elevator counting with reversal 13 10.9 3.7 5-18 19 9.6 3.7 2-15 
Telephone search 16 7.6 3.5 0-12 21 8.1 3.4 0-15 
Telephone search while counting 16 8.2 3.7 0-15 21 8.6 3.6 0-15 
Lottery 17 7.8 4.1 1-13 20 9.6 3.3 4-13 
  
 Table 3. Most frequently requested text messages 
 Group 1 
NeuroPage then control 
Percentage of messages Group 2 
Control then NeuroPage 
Percentage of messages 
NeuroPage 
Condition: Requested 
content 
Medication 36 Medication  47 
Toilet 10 Today is 11 
Drink 8 Check calendar/diary 8 
Eat meal 7 Charge phone 6 
Check calendar/diary 6 Eat meal 4 
Today is  4 Prepare food 3 
Control Condition: 
Requested content  
Current affairs 68 Current affairs 51 
Sports news 15 Specific news 36 
Specific news 13 Sports news 13 
Quotes 4   
  
 Table 4. Comparison of conditions on outcome measures 
Measure NeuroPage  Control Comparison 
n Mean SD Range n Mean SD Range t df p Cohen’s d 
Everyday Memory Questionnaire 27 40.3 22.9 1-83 29 40.7 21.3 4-90 0.12 24 0.90 0.02 
General Health Questionnaire 24 31.9 12.6 8-61 26 39.7 16.2 21-77 -3.83 20 0.001* -0.84*** 
AMEDO Part A Coping strategies 24 38.5 7.9 19-52 25 38.5 6.7 25-51 0.23 20 0.82 0.05 
AMEDO Part B1 External  Aids 24 14.2 2.7 9-16 25 13.7 3.2 4-16 1.11 20 0.28 0.24 
AMEDO Part B2 Internal Aids 22 11.2 3.7 4-16 21 12.2 3.7 4-16 -1.92 17 0.07 -0.45 
EQ5D Mobility 24 2.0 0.4 1-3 24 1.9 0.5 1-3 1.83 19 0.08 0.41 
EQ5D Self Care 24 1.6 0.5 1-2 25 1.6 0.6 1-3 -0.44 20 0.67 -0.10 
EQ5D Usual Activities 24 2.0 0.4 1-3 25 2.0 0.7 1-3 0.33 20 0.75 0.07 
EQ5D Pain/ Discomfort  24 2.3 0.6 1-3 25 2.2 0.7 1-3 0.44 20 0.67 0.10 
EQ5D Anxiety/Depression 24 1.6 0.6 1-3 25 1.8 0.6 1-3 -2.17 20 0.04* -0.47 
EQ5D Visual Analogue Scale 23 53.2 26.4 14-100 24 44.5 22.5 9-92 2.03 19 0.06 0.45 
Everyday Memory Questionnaire -Informant  20 35.0 19.7 0-71 20 33.2 18.9 1-91 -1.66 16 0.12 -0.40 
Daily Diary 
% target behaviours forgotten 
20 8.8 9.9 0-53 20 30.0 33.9 0-100 -2.88 19 0.01* -0.64** 
*significant treatment effect p<0.05 
 ** moderate effect size d>0.5 
*** large effect size d>0.8 
 
EMQ Everyday Memory Questionnaire 
AMEDO Adaptation to Memory Difficulties Outcome measure 
EQ5D EuroQuol 5 Dimensions 
  
Figure 1.  NeuroPage timetable example 
 
Figure 2 Control timetable example 
 
Figure 3. Flow of participants through the trial 
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